Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22547106 | 1.00 | TSHR (0.47) | TSHRHTTSMN1; SMN2LMNANPSR1 | |
| SCHEMBL18957388 | 0.90 | BCAT2 (0.50) | TSHRHTTNPSR1CYP1A2CYP2C9 | |
| SCHEMBL22529903 | 0.86 | MEN1 (0.47) | HTTSMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29351760 | 0.86 | MEN1 (0.47) | HTTSMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL22529945 | 0.83 | CYP11B1 (0.49) | HTTSMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29349924 | 0.83 | CYP11B1 (0.49) | HTTSMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29352652 | 0.77 | CD38 (0.36) | SMN1; SMN2HPGDMEN1KMT2AMAPT | |
| SCHEMBL22529908 | 0.77 | CD38 (0.36) | SMN1; SMN2HPGDMEN1KMT2AMAPT | |
| SCHEMBL29351832 | 0.76 | LOXL2 (0.43) | MEN1KMT2AMAPTRAB9AMAP4K4 | |
| SCHEMBL22529974 | 0.76 | LOXL2 (0.43) | MEN1KMT2AMAPTRAB9AMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994001-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-11-22 | — | — | CN | claimed |
| EP-3953335-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Cellestia Biotech AG (CH) | 2022-02-16 | — | — | EP | claimed |
| CN-113966324-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2022-01-21 | — | — | CN | claimed |
| CN-118994001-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-113966324-B | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2022-06-02 | — | — | US | disclosed |
| EP-3953335-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Cellestia Biotech AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| CN-113966324-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | NOTCH1, NOTCH4, NOTCH2 | TSHR 4398/4885HTT 4521/4885SMN1; SMN2 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.